Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorETIENNE, Marie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorVERDOUX, Helene
IDREF: 115951903
dc.date.accessioned2025-03-26T14:34:28Z
dc.date.available2025-03-26T14:34:28Z
dc.date.issued2025-03-10
dc.identifier.issn1573-2509en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/205701
dc.description.abstractEnThere is still no consensus regarding the indications of long-acting injectable antipsychotics (LAIs) in early psychosis (EP). This umbrella review synthesizes findings from systematic reviews and meta-analyses on the risk-benefit balance of LAIs in EP. Eligible systematic reviews and meta-analyses on LAIs in EP were identified by a MEDLINE search from inception until June 2024. Data were synthesized narratively. Seven systematic reviews and four meta-analyses published from 2007 to 2024 were identified. They included 220 to 14,313 participants recruited in 58 primary unique randomized controlled trials or observational studies. All LAIs were considered in most reviews. Inclusion criteria and diagnoses differed widely across the selected reviews. The reviews and meta-analyses consistently showed a positive impact of LAIs on symptomatic outcome in people with EP, although there was no consensus on whether LAIs outperformed oral anti-psychotics (OAPs). Most reported a greater reduction of treatment discontinuation due to inefficacy or nonadherence with LAIs vs. OAPs, although meta-analyses found no difference between LAIs vs. OAPs regarding all-cause discontinuation. Findings regarding relapse prevention were inconclusive. Similar rates of metabolic adverse drug reaction and potentially lower rates of extrapyramidal symptoms were observed with LAIs vs. OAPs. LAIs should be considered according to users' preferences and could be particularly useful for people with a poor medication adherence risk profile. Further high-quality observational studies in real-life prescribing conditions are needed to support robust recommendations for clinical practice regarding indications of LAIs in EP.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enEarly psychosis
dc.subject.enFirst-episode psychosis
dc.subject.enLong-acting injectable antipsychotics
dc.subject.enUmbrella review
dc.title.enImpact of long-acting injectable antipsychotics in early psychosis: An umbrella review
dc.title.alternativeSchizophr Resen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.schres.2025.03.002en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed40068445en_US
bordeaux.journalSchizophrenia Researchen_US
bordeaux.page140-150en_US
bordeaux.volume277en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-05007075
hal.version1
hal.date.transferred2025-03-26T14:34:30Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Schizophrenia%20Research&rft.date=2025-03-10&rft.volume=277&rft.spage=140-150&rft.epage=140-150&rft.eissn=1573-2509&rft.issn=1573-2509&rft.au=ETIENNE,%20Marie&VERDOUX,%20Helene&rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record